Certain cancers show different effects at particular interfaces, such as TP53-TP53BP2, which is predicted to be strongly disabled in low grade glioma and weakly disabled in hepatocellular carcinoma owing to different mutational preferences of the principal contacting residues (Fig. 3a,b). This evidence concerns the gene TP53BP2 and central nervous system cancer.